Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | RECQL | P46063 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | DAO | P14920 | 5/20 | 0.56 |
| ▸ | LDHA | P00338 | 2/20 | 0.56 |
| ▸ | IDH1 | O75874 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL413966 | 0.86 | RAB9A (0.76) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL9010390 | 0.85 | DAO (0.68) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL11863320 | 0.85 | LOXL2 (0.57) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL2116138 | 0.85 | KMT2A (0.59) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL2432852 | 0.85 | RAB9A (0.56) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL1584925 | 0.85 | RAB9A (0.56) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL17440151 | 0.85 | MEN1 (0.73) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL103357 | 0.83 | RAB9A (0.76) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL20300582 | 0.82 | RAB9A (0.70) | RAB9ANPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL6170692 | 0.82 | RAB9A (0.52) | RAB9ANPC1CYP1A2CYP2C19RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134688-B1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC (CA) | 2016-10-05 | — | — | EP | claimed |
| US-8026261-B2 | neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one | APOTEX TECHNOLOGIES INC. (CA) | 2011-09-27 | — | — | US | claimed |
| EP-2134688-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | Apotex Technologies Inc. (CA) | 2009-12-23 | — | — | EP | claimed |
| WO-2008116301-A1 | FLUORINATED DERIVATIVES OF DEFERIPRONE | APOTEX TECHNOLOGIES INC. (CA) | 2008-10-02 | — | — | WO | claimed |
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | APOTEX TECHNOLOGIES INC. | 2008-10-02 | — | — | US | claimed |
| CN-113651786-B | Method for synthesizing 6-hydroxy-2-ethyl-2H-pyrone- [3] by catalyzing oxidation of alpha-furopropanol and product thereof | 上海万香日化有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-116669727-A | Triazole-pyridinyl substituted azacyclohexylacetic acid compounds as LPA receptor antagonists | 唯久生物有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-115010826-B | Chitosan oligosaccharide-hydroxypyridone conjugate, and preparation method and application thereof | 浙江工商大学 | 2023-07-18 | — | — | CN | disclosed |
| EP-4196220-A1 | TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS | Viva Star Biosciences Limited (HK) | 2023-06-21 | — | — | EP | disclosed |
| US-20220402873-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | AUTOTAC INC. (KR) | 2022-12-22 | — | — | US | disclosed |
| US-20220402873-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | AUTOTAC INC. (KR) | 2022-12-22 | — | — | US | disclosed |
| CN-115010826-A | Chitosan oligosaccharide-hydroxypyridone conjugate and preparation method and application thereof | 浙江工商大学 | 2022-09-06 | — | — | CN | disclosed |
| US-4705871-A | Aralkoxy and aryloxyalkoxy kojic acid derivatives | G. D. SEARLE & CO. (US) | 1987-11-10 | — | — | US | disclosed |
| EP-0243924-A2 | 2-Oxo-1-(substituted phosphorous)azetidines | E.R. Squibb & Sons, Inc. (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4644071-A | Aralkoxy and aryloxyalkoxy kojic acid derivatives | G. D. SEARLE & CO. (US) | 1987-02-17 | — | — | US | disclosed |
| EP-0209751-A2 | Cephalosporin derivatives and bactericides containing the same | MEIJI SEIKA KAISHA LTD. (JP) | 1987-01-28 | — | — | EP | disclosed |
| US-4632985-A | 3-acylamino-2-oxo-1-azetidinesulfonic acids | E. R. SQUIBB & SONS, INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0204207-A1 | 3-acylamino-2-oxo-1-azetidinesulfonic acids | E.R. Squibb & Sons, Inc. (US) | 1986-12-10 | — | — | EP | disclosed |
| US-4603144-A | Kojic acid ether-ester derivatives | G. D. SEARLE & CO. (US) | 1986-07-29 | — | — | US | disclosed |
| EP-0171814-A1 | Kojic acid ether-ester derivatives | G.D. Searle & Co. (US) | 1986-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242706-A1 | Fluorinated derivatives of deferiprone | SLC40A1, TFRC, FECH | RAB9A 509/4885NPC1 104/4885CYP1A2 1377/4885 |
| US-20220402873-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | SQSTM1, ATG7, ATG13 | RAB9A 217/4885NPC1 291/4885CYP1A2 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.